34
Participants
Start Date
April 30, 2015
Primary Completion Date
September 20, 2024
Study Completion Date
September 20, 2024
Pembrolizumab
Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
Radiotherapy
Radiofrequency ablation
Memorial Sloan Kettering Cancer Center, New York
Merck Sharp & Dohme LLC
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER